AHA Coding Clinic® for HCPCS - 2013 Quarter 3; For Your Information
New HCPCS codes for certain drugs and biologicals
The CMS has created two new HCPCS codes for the reporting of certain drugs and biologicals in the hospital outpatient setting. The new HCPCS codes listed below were effective for the reporting of services since July 1, 2013. HCPCS Long descriptor Q2050 * Injection, Doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg Q2051 ** Injection, Zoledronic acid, not otherwise specified, 1 mg Doxorubicin is a drug utilized in cancer chemotherapy treatment and Zoledronic acid is utilized in the treatment of a variety of bone disorders. *HCPCS code Q2050 replaced HCPCS code J9002 , Injection, Doxorubicin Hydrochloride, Liposomal, Doxil, 10 mg...
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS HCPCS update for hospital outpatient reporting of certain drugs and biologicals. It focuses on newly created codes, their effective date, and the related prior codes that were replaced, making it relevant to hospital outpatient billing staff, coders, and reimbursement professionals tracking HCPCS changes.
Why This Topic Matters
HCPCS updates can affect charge capture, claim reporting, and continuity when older billing identifiers are replaced. Readers who work with outpatient drug reporting or code maintenance will want to know which services the article addresses and when the changes took effect.
What You Will Learn
- Which HCPCS reporting changes were announced for selected drugs and biologicals
- When the updated reporting changes became effective
- How the article frames the relationship between new and prior HCPCS identifiers
- Which general outpatient reporting context the update applies to
Who Should Read This
- Hospital outpatient coders
- Billing and reimbursement staff
- Revenue cycle professionals
- Coding managers
- Compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com